Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Algernon Pharmaceuticals Inc (OP: AGNPF )

1.585 UNCHANGED
Streaming Delayed Price Updated: 3:40 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.585
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.585
Today's Range 1.585 - 1.585
52wk Range 1.475 - 6.040
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed 
Via Benzinga
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs. 
Via Benzinga

Performance

YTD
-5.65%
-5.65%
1 Month
-3.94%
-3.94%
3 Month
-27.63%
-27.63%
6 Month
-41.73%
-41.73%
1 Year
-73.76%
-73.76%

More News

Read More
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Via Benzinga
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Via Benzinga
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Via Benzinga
Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video
Via Newsfile
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
Via Benzinga
A Foundational Study On Stroke Is Ready. Here Is Why It's Important
Via Benzinga
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
Via Benzinga
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
Via Benzinga
The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News
From The Market Herald
Via AccessWire
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Via Benzinga
The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News
From The Market Herald
Via AccessWire
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Via Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Via Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
Via Talk Markets
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
Via Benzinga
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.